Xin Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xin Lu has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Jin Bian
Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
15 shared publications- Haitao Zhao
Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
11 shared publications Hanchun Huang
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
8 shared publicationsAnqiang Wang
Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, 100730, China
6 shared publicationsJunwei Zhang
Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
6 shared publicationsYiyao Xu
Department of Liver Surgery, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
6 shared publications
Latest Publications
- Open Access
- 10 February 2023
- Published by Gavin Publishers in Annals of Medical and Clinical Oncology
- Vol. 6 (1)
Differential Expression of Necroptosis-Related Genes with regulating lncRNA in Triple Negative Breast Cancer to Predict Prognosis and Immunotherapy Response
Purpose : Necroptosis is essential in tumor biology in which lncRNAs play an important role but related studies in triple negative breast cancer (TNBC) were insufficient. We aim to screen remarkable necroptosis-related lncRNA and construct a lncNRA-related risk model for precision of immunotherapy. Methods: Transcriptional data were acquired from TCGA database. Differentially expressed genes (DEGs) related to necroptosis were obtained in TNBC samples. LncRNAs related to DEGs were analyzed by following Cox and least absolute shrinkage and selection operator regression analysis. Prognosis-associated lncRNAs were brought into a model which divided training and testing samples into high-/low-risk subgroups. Survival analysis between these subgroups were conducted and independent variables of prognosis were selected. Nomogram was then created to predict prognosis of selected patients. Comparisons of immune landscape, tumor microenvironment, and immunotherapy response were performed between the two subgroups. Results: Seven necroptosis-related DEGs (NRGs) were found in TNBC. Six of 153 NRG-related lncRNAs were brought into model. Forecast performance was validated in testing datasets. Immune cell infiltration and T-cell activity was weaker in high-risk group compared with that in low-risk counterparts. Innate and adaptive immune cell abundance was inversely proportional to risk score. Compared with low-risk group, patients in high-risk group had lower immune/stromal/ESTIMATE score, lower expression of immune checkpoint molecules, and worse immunotherapy response. Conclusion: Six NRG-related lncRNAs were potential targets for future precision therapy of TNBC. Our model was effective in predicting the prognosis of TNBC patients and beneficial for decision-making of immunotherapy. Keywords: Triple-negative breast cancer; Necroptosis, lncRNA; Risk model; Prognosis; Immune landscape Abbreviations BC: Breast Cancer CTLA-4: Cytotoxic T Lymphocyte-Associated Antigen-4 DC: Dendritic Cell DEG: Differentially Expressed Genes ER: Estrogen Receptor FC: Fold Change FDR: False Discovery Rate FPKM: Fragments Per Kilobase of Exon model per Million mapped fragments GSEA: Gene Set Enrichment Analysis HCC: Hepatocellular Carcinoma HDAC: Histone Deacetylase 9 HER-2: Human Epidermal Growth Factor Receptor 2 HR: Hazard Ratio ICI: Immune Checkpoint Inhibitor IPS: ImmunoPhenoScore KEGG: Kyoto Encyclopedia of Genes and Genomes LASSO: Least Absolute Shrinkage and Selection Operator lncRNA: Long Non-coding RNA MLKL: Mixed Lineage Kinase domain-like proteins NK: Natural Killer NRG: Necroptosis-Related Gene NTNBC: Non-Triple-Negative Breast Cancer PD-1: Programmed Death-1 PLA2G4E : Phospholipase A2 group IVE PR: Progesterone Receptor RIPK1/3: Receptor-Interacting serine/Threonine-Protein Kinase 1/3 ROC: Receiver Operating Characteristic ROS: Reactive Oxygen Species ssGSEA: Single Sample Gene Set Enrichment Analysis TCGA: The Cancer Genome Atlas TCIA: The Cancer Immunome Atlas TME: Tumor microenvironment TNBC: Triple-Negative Breast Cancer
- 10 February 2023
- Published by Gavin Publishers in Annals of Medical and Clinical Oncology
- Vol. 6 (1)
Open AccessDifferential Expression of Necroptosis-Related Genes with regulating lncRNA in Triple Negative Breast Cancer to Predict Prognosis and Immunotherapy Response
Purpose : Necroptosis is essential in tumor biology in which lncRNAs play an important role but related studies in triple negative breast cancer (TNBC) were insufficient. We aim to screen remarkable necroptosis-related lncRNA and construct a lncNRA-related risk model for precision of immunotherapy. Methods: Transcriptional data were acquired from TCGA database. Differentially expressed genes (DEGs) related to necroptosis were obtained in TNBC samples. LncRNAs related to DEGs were analyzed by following Cox and least absolute shrinkage and selection operator regression analysis. Prognosis-associated lncRNAs were brought into a model which divided training and testing samples into high-/low-risk subgroups. Survival analysis between these subgroups were conducted and independent variables of prognosis were selected. Nomogram was then created to predict prognosis of selected patients. Comparisons of immune landscape, tumor microenvironment, and immunotherapy response were performed between the two subgroups. Results: Seven necroptosis-related DEGs (NRGs) were found in TNBC. Six of 153 NRG-related lncRNAs were brought into model. Forecast performance was validated in testing datasets. Immune cell infiltration and T-cell activity was weaker in high-risk group compared with that in low-risk counterparts. Innate and adaptive immune cell abundance was inversely proportional to risk score. Compared with low-risk group, patients in high-risk group had lower immune/stromal/ESTIMATE score, lower expression of immune checkpoint molecules, and worse immunotherapy response. Conclusion: Six NRG-related lncRNAs were potential targets for future precision therapy of TNBC. Our model was effective in predicting the prognosis of TNBC patients and beneficial for decision-making of immunotherapy. Keywords: Triple-negative breast cancer; Necroptosis, lncRNA; Risk model; Prognosis; Immune landscape Abbreviations BC: Breast Cancer CTLA-4: Cytotoxic T Lymphocyte-Associated Antigen-4 DC: Dendritic Cell DEG: Differentially Expressed Genes ER: Estrogen Receptor FC: Fold Change FDR: False Discovery Rate FPKM: Fragments Per Kilobase of Exon model per Million mapped fragments GSEA: Gene Set Enrichment Analysis HCC: Hepatocellular Carcinoma HDAC: Histone Deacetylase 9 HER-2: Human Epidermal Growth Factor Receptor 2 HR: Hazard Ratio ICI: Immune Checkpoint Inhibitor IPS: ImmunoPhenoScore KEGG: Kyoto Encyclopedia of Genes and Genomes LASSO: Least Absolute Shrinkage and Selection Operator lncRNA: Long Non-coding RNA MLKL: Mixed Lineage Kinase domain-like proteins NK: Natural Killer NRG: Necroptosis-Related Gene NTNBC: Non-Triple-Negative Breast Cancer PD-1: Programmed Death-1 PLA2G4E : Phospholipase A2 group IVE PR: Progesterone Receptor RIPK1/3: Receptor-Interacting serine/Threonine-Protein Kinase 1/3 ROC: Receiver Operating Characteristic ROS: Reactive Oxygen Species ssGSEA: Single Sample Gene Set Enrichment Analysis TCGA: The Cancer Genome Atlas TCIA: The Cancer Immunome Atlas TME: Tumor microenvironment TNBC: Triple-Negative Breast Cancer
- Open Access
- 3 August 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 843707
Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
Introduction: Hyperprogressive disease (HPD) is a paradoxically rapid disease progression during or shortly after antitumor treatment, especially immune checkpoint inhibitors (ICIs). Various diagnosis criteria of HPD cause heterogeneous incidence rates in different clinical research, and there is no consensus on potential risk factors associated with HPD occurrence. Hence, we aimed to summarize incidence of HPD in ICI treatment for solid tumors. Clinicopathological factors associated with HPD are also analyzed.Methods: Clinical studies about HPD during/after ICI treatment of solid malignancies are included. Pubmed, Embase, and Cochrane library were searched for eligible studies published before October 7. The Newcastle–Ottawa scale was used to assess the quality of the included studies. Random effect and fixed effect models were, respectively, used for pooling incidence of HPD and analysis of risk factors for HPD. Heterogeneity, subgroup analysis, and publication bias were also analyzed. All meta-analysis was performed via R software (y -40v4.0.2).Results: Forty-one studies with 6009 patients were included. The pooled incidence of HPD was 13.2% (95% CI, 11.2%–15.4%). Head and neck cancer (HNC) had the highest incidence of HPD (18.06%), and melanoma had the lowest (9.9%). Tumor types (P = .0248) and gender ratio (P = .0116) are sources of heterogeneity of pooled incidence of HPD. For five clinicopathological factors associated with HPD, only programmed cell death protein 1 ligand 1 (PD-L1) positivity was a preventive factor (odds ratio = 0.61, P <.05). High lactate dehydrogenase (LDH) level (OR = 1.51, P = .01), metastatic sites >2 (OR = 2.38, P <.0001), Eastern Cooperative Oncology Group Performance Score ≥2 (OR = 1.47, P = .02), and liver metastasis (OR = 3.06, P <.0001) indicate higher risk of HPD.Conclusions: The pooled incidence of HPD was less than 15%, and HNC had the highest incidence of HPD. LDH and PD-L1 are remarkable biomarkers for prediction of HPD in future medical practice.
- 3 August 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 843707
Open AccessHyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
Introduction: Hyperprogressive disease (HPD) is a paradoxically rapid disease progression during or shortly after antitumor treatment, especially immune checkpoint inhibitors (ICIs). Various diagnosis criteria of HPD cause heterogeneous incidence rates in different clinical research, and there is no consensus on potential risk factors associated with HPD occurrence. Hence, we aimed to summarize incidence of HPD in ICI treatment for solid tumors. Clinicopathological factors associated with HPD are also analyzed.Methods: Clinical studies about HPD during/after ICI treatment of solid malignancies are included. Pubmed, Embase, and Cochrane library were searched for eligible studies published before October 7. The Newcastle–Ottawa scale was used to assess the quality of the included studies. Random effect and fixed effect models were, respectively, used for pooling incidence of HPD and analysis of risk factors for HPD. Heterogeneity, subgroup analysis, and publication bias were also analyzed. All meta-analysis was performed via R software (y -40v4.0.2).Results: Forty-one studies with 6009 patients were included. The pooled incidence of HPD was 13.2% (95% CI, 11.2%–15.4%). Head and neck cancer (HNC) had the highest incidence of HPD (18.06%), and melanoma had the lowest (9.9%). Tumor types (P = .0248) and gender ratio (P = .0116) are sources of heterogeneity of pooled incidence of HPD. For five clinicopathological factors associated with HPD, only programmed cell death protein 1 ligand 1 (PD-L1) positivity was a preventive factor (odds ratio = 0.61, P <.05). High lactate dehydrogenase (LDH) level (OR = 1.51, P = .01), metastatic sites >2 (OR = 2.38, P <.0001), Eastern Cooperative Oncology Group Performance Score ≥2 (OR = 1.47, P = .02), and liver metastasis (OR = 3.06, P <.0001) indicate higher risk of HPD.Conclusions: The pooled incidence of HPD was less than 15%, and HNC had the highest incidence of HPD. LDH and PD-L1 are remarkable biomarkers for prediction of HPD in future medical practice.
- Open Access
- 17 April 2022
- Published by Springer Nature in BMC Surgery
- Vol. 22 (1) , 1-14
Clinicopathological characteristics and treatment outcomes of occult breast cancer: a population-based study
Background: Occult breast cancer (OBC) is a special type of breast cancer. Because of its rarity, clinicopathological information is still insufficient, causing a controversial condition about its treatment recommendation. Thus, we aimed to clarify major clinicopathological information, treatment strategies and prognosis of OBC based on a large population. Methods: We retrospectively collected adult female OBC population from Surveillance, Epidemiology, and End Results database. We divided the whole cohort into two groups based on surgical treatment in-breast. Descriptive analysis of 18 clinicopathological variables was conducted. Survival analysis was performed based on different clinicopathological factors. Univariate and multivariate Cox regression analysis was performed to identify potential independent predictor for prognosis of OBC. Results: 1189 OBC patients were in final analysis and most of them were diagnosed as an early-stage carcinoma. Patients received breast-conserving treatment (BCT) was nearly two times of ones received mastectomy. Patients receiving radiotherapy in BCT group were significantly more than patients receiving radiotherapy in mastectomy group (61.76 vs. 50.9%, P < 0.001). After a median follow-up period of 62 months, 5-year and 10-year overall survival (OS) of all subjects was 81.6% and 68.8%, respectively. No significant difference in OS and breast-cancer specific survival (BCSS) was found between mastectomy and local breast-conserving surgery. Older age and larger number of positive lymph nodes causes a worse prognosis whereas radiotherapy brought a better clinical outcome for OBC patients. Conclusions: OBC has a generally good prognosis. Less-intensive surgery does not negatively impact clinical outcomes of OBC while additional radiotherapy is totally beneficial to prolong OS and BCSS.
- 17 April 2022
- Published by Springer Nature in BMC Surgery
- Vol. 22 (1) , 1-14
Open AccessClinicopathological characteristics and treatment outcomes of occult breast cancer: a population-based study
Background: Occult breast cancer (OBC) is a special type of breast cancer. Because of its rarity, clinicopathological information is still insufficient, causing a controversial condition about its treatment recommendation. Thus, we aimed to clarify major clinicopathological information, treatment strategies and prognosis of OBC based on a large population. Methods: We retrospectively collected adult female OBC population from Surveillance, Epidemiology, and End Results database. We divided the whole cohort into two groups based on surgical treatment in-breast. Descriptive analysis of 18 clinicopathological variables was conducted. Survival analysis was performed based on different clinicopathological factors. Univariate and multivariate Cox regression analysis was performed to identify potential independent predictor for prognosis of OBC. Results: 1189 OBC patients were in final analysis and most of them were diagnosed as an early-stage carcinoma. Patients received breast-conserving treatment (BCT) was nearly two times of ones received mastectomy. Patients receiving radiotherapy in BCT group were significantly more than patients receiving radiotherapy in mastectomy group (61.76 vs. 50.9%, P < 0.001). After a median follow-up period of 62 months, 5-year and 10-year overall survival (OS) of all subjects was 81.6% and 68.8%, respectively. No significant difference in OS and breast-cancer specific survival (BCSS) was found between mastectomy and local breast-conserving surgery. Older age and larger number of positive lymph nodes causes a worse prognosis whereas radiotherapy brought a better clinical outcome for OBC patients. Conclusions: OBC has a generally good prognosis. Less-intensive surgery does not negatively impact clinical outcomes of OBC while additional radiotherapy is totally beneficial to prolong OS and BCSS.
- Open Access
- 2 April 2022
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 10 (9) , 508
The efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: a systematic review and meta-analysis
The efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: a systematic review and meta-analysis Zijun Zhao, Junwei Zhang, Jin Bian, Xin Lu
- 2 April 2022
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 10 (9) , 508
Open AccessThe efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: a systematic review and meta-analysis
The efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: a systematic review and meta-analysis Zijun Zhao, Junwei Zhang, Jin Bian, Xin Lu
- Open Access
- 29 January 2022
- Published by Springer Nature in Biochemical Genetics
- Vol. 60 (5) , 1762-1780
Key Genes Associated with Tumor-Infiltrating Non-regulatory CD4- and CD8-Positive T Cells in Microenvironment of Hepatocellular Carcinoma
The immune microenvironment in hepatocellular carcinoma (HCC), especially T-cell infiltration, plays a key role in the prognosis and drug sensitivity of HCC. Our study aimed to analyze genes related to non-regulatory CD4+and CD8+T cell in HCC. Data of HCC samples were downloaded from The Cancer Genome Atlas (TCGA) database. According to stromal and immune score retrieved by Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data (ESTIMATE) algorithm, differentiated expressed genes (DEGs) between high and low stromal/immune scoring groups were collected. Using Cibersort algorithm, abundance of immune cells was calculated and genes related with CD4+and CD8+T cells were selected. Protein–protein interaction (PPI) networks and networks of microRNA (miRNA)–target gene interactions were illustrated, in which CD4+and CD8+T cell-related core genes were selected. Finally, Cox regression test and Kaplan–Meier (K–M) survival analysis were conducted. Totally, 1579 DEGs were identified, where 103 genes and 407 genes related with CD4+and CD8+T cell were selected, respectively. Each of 30 core genes related to CD4+T cells and CD8+T cells were selected by PPI network. Four genes each related with the two types of T cells had a significant impact on prognosis of HCC patients. Amongst, KLRB1 and IL18RAP were final two genes related to both two kinds of T cells and associated with overall survival of the HCC patients.
- 29 January 2022
- Published by Springer Nature in Biochemical Genetics
- Vol. 60 (5) , 1762-1780
Open AccessKey Genes Associated with Tumor-Infiltrating Non-regulatory CD4- and CD8-Positive T Cells in Microenvironment of Hepatocellular Carcinoma
The immune microenvironment in hepatocellular carcinoma (HCC), especially T-cell infiltration, plays a key role in the prognosis and drug sensitivity of HCC. Our study aimed to analyze genes related to non-regulatory CD4+and CD8+T cell in HCC. Data of HCC samples were downloaded from The Cancer Genome Atlas (TCGA) database. According to stromal and immune score retrieved by Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data (ESTIMATE) algorithm, differentiated expressed genes (DEGs) between high and low stromal/immune scoring groups were collected. Using Cibersort algorithm, abundance of immune cells was calculated and genes related with CD4+and CD8+T cells were selected. Protein–protein interaction (PPI) networks and networks of microRNA (miRNA)–target gene interactions were illustrated, in which CD4+and CD8+T cell-related core genes were selected. Finally, Cox regression test and Kaplan–Meier (K–M) survival analysis were conducted. Totally, 1579 DEGs were identified, where 103 genes and 407 genes related with CD4+and CD8+T cell were selected, respectively. Each of 30 core genes related to CD4+T cells and CD8+T cells were selected by PPI network. Four genes each related with the two types of T cells had a significant impact on prognosis of HCC patients. Amongst, KLRB1 and IL18RAP were final two genes related to both two kinds of T cells and associated with overall survival of the HCC patients.
- 1 January 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 161, 23-25
Primary yolk sac tumour of the liver: A diagnostic pitfall
- 1 January 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 161, 23-25
Primary yolk sac tumour of the liver: A diagnostic pitfall
- 20 December 2021
- Published by Wolters Kluwer Health in Hepatology
- Vol. 75 (4) , 1058-1059
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency
- 20 December 2021
- Published by Wolters Kluwer Health in Hepatology
- Vol. 75 (4) , 1058-1059
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency
- Open Access
- 28 September 2021
- Published by Springer Nature in Research Square
Clinicopathological Characteristics and Treatment Outcomes of Occult Breast Cancer: A Population-Based Study
Background Occult breast cancer (OBC) is a special type of breast cancer. It is defined as an axillary lymph node metastasis without ipsilateral breast malignancy according to mammogram and ultrasonography. Because of its rarity and no primary lesion, clinicopathological information is still insufficient, causing a controversial condition about its treatment recommendation. In this study, we aimed to clarify major clinicopathological information, treatment strategies and prognosis of OBC based on a large population. Methods We retrospectively collected adult female OBC population from Surveillance, Epidemiology, and End Results (SEER) database. We divided the whole OBC cohort into two groups based on surgical treatment. Descriptive analysis of 18 clinicopathological variables was conducted by Wilcoxin rank sum test, Chi-square and Fisher’s exact test. Survival analysis was performed in the whole cohort as well as based on different clinicopathological factors. Univariate and multivariate Cox regression analysis was performed to identify potential independent predictor for prognosis of OBC. Results 1189 OBC patients was included in final analysis. Elderly patients predominated with a mean age of nearly 60. Most of the OBC patients were diagnosed as an early-stage carcinoma and ductal carcinoma took up nearly 40% of all the histological types of OBC. Luminal A is the commonest subtypes of OBC. For in-breast treatment, number of patients received mastectomy was 4 times more than that of patients received breast-conserving surgery (BCS). More than 70% patients receiving BCS took radiotherapy, significantly more than the portion of patients receiving radiation in mastectomy group (50.9%, P < 0.001). Median follow-up period of all subjects was about 62 months. 5-year and 10-year overall survival (OS) of the complete OBC cohort was 81.6% and 68.8%, respectively. No significant difference in OS and breast-cancer specific survival (BCSS) was found between mastectomy and BCS. Older age and larger number of positive lymph nodes causes a worse prognosis whereas radiotherapy brought a better clinical outcome for OBC patients. Conclusion OBC is a rare breast malignancy with a generally good prognosis. Less-intensive surgical intervention does not negatively impact clinical outcomes of OBC while additional radiotherapy is totally beneficial to prolong OS and BCSS.
- 28 September 2021
- Published by Springer Nature in Research Square
Open AccessClinicopathological Characteristics and Treatment Outcomes of Occult Breast Cancer: A Population-Based Study
Background Occult breast cancer (OBC) is a special type of breast cancer. It is defined as an axillary lymph node metastasis without ipsilateral breast malignancy according to mammogram and ultrasonography. Because of its rarity and no primary lesion, clinicopathological information is still insufficient, causing a controversial condition about its treatment recommendation. In this study, we aimed to clarify major clinicopathological information, treatment strategies and prognosis of OBC based on a large population. Methods We retrospectively collected adult female OBC population from Surveillance, Epidemiology, and End Results (SEER) database. We divided the whole OBC cohort into two groups based on surgical treatment. Descriptive analysis of 18 clinicopathological variables was conducted by Wilcoxin rank sum test, Chi-square and Fisher’s exact test. Survival analysis was performed in the whole cohort as well as based on different clinicopathological factors. Univariate and multivariate Cox regression analysis was performed to identify potential independent predictor for prognosis of OBC. Results 1189 OBC patients was included in final analysis. Elderly patients predominated with a mean age of nearly 60. Most of the OBC patients were diagnosed as an early-stage carcinoma and ductal carcinoma took up nearly 40% of all the histological types of OBC. Luminal A is the commonest subtypes of OBC. For in-breast treatment, number of patients received mastectomy was 4 times more than that of patients received breast-conserving surgery (BCS). More than 70% patients receiving BCS took radiotherapy, significantly more than the portion of patients receiving radiation in mastectomy group (50.9%, P < 0.001). Median follow-up period of all subjects was about 62 months. 5-year and 10-year overall survival (OS) of the complete OBC cohort was 81.6% and 68.8%, respectively. No significant difference in OS and breast-cancer specific survival (BCSS) was found between mastectomy and BCS. Older age and larger number of positive lymph nodes causes a worse prognosis whereas radiotherapy brought a better clinical outcome for OBC patients. Conclusion OBC is a rare breast malignancy with a generally good prognosis. Less-intensive surgical intervention does not negatively impact clinical outcomes of OBC while additional radiotherapy is totally beneficial to prolong OS and BCSS.
- Open Access
- 1 August 2021
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 10 (4) , 434-442
Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy
Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy Xiaobo Yang, Haifeng Xu, Bangyou Zuo, Xu Yang, Jin Bian, Junyu Long, Dongxu Wang, Junwei Zhang, Cong Ning, Yanyu Wang, Ziyu Xun, Yunchao Wang, Xin Lu, Yilei Mao, Xinting Sang, Haitao Zhao
- 1 August 2021
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 10 (4) , 434-442
Open AccessDownstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy
Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy Xiaobo Yang, Haifeng Xu, Bangyou Zuo, Xu Yang, Jin Bian, Junyu Long, Dongxu Wang, Junwei Zhang, Cong Ning, Yanyu Wang, Ziyu Xun, Yunchao Wang, Xin Lu, Yilei Mao, Xinting Sang, Haitao Zhao
- 9 July 2021
- Published by Wolters Kluwer Health in Hepatology
- Vol. 74 (5) , 2924
Letter to the Editor: Is Aspirin a Drug or Just a Marker for Biliary Cancer?
The research by Liao et al.(1) showed that postdiagnosis aspirin use improved the mortality of various subtypes of biliary tract cancer (BTC). The results were impressive, with the adjusted hazard ratios of mortality ranging from 0.51 to 0.58, and all subgroup analyses were statistically significant. However, we think that some other aspects should be discussed.
- 9 July 2021
- Published by Wolters Kluwer Health in Hepatology
- Vol. 74 (5) , 2924
Letter to the Editor: Is Aspirin a Drug or Just a Marker for Biliary Cancer?
The research by Liao et al.(1) showed that postdiagnosis aspirin use improved the mortality of various subtypes of biliary tract cancer (BTC). The results were impressive, with the adjusted hazard ratios of mortality ranging from 0.51 to 0.58, and all subgroup analyses were statistically significant. However, we think that some other aspects should be discussed.